TABLE 2.
VAS score trends over 72 h based on intention-to-treat and per-protocol analyses.
| Parameters | Intention-to-treat analysis | Per-protocol analysis | ||||
|---|---|---|---|---|---|---|
| Group | Hydromorphone (n = 39) | Pethidine (n = 38) | p-value | Hydromorphone (n = 36) | Pethidine (n = 36) | p-value |
| 0 h VAS, median (IQR) | 6 (6–7) | 6 (5–6) | 0.261 | 6 (6–7) | 6 (5–6) | 0.246 |
| 4 h VAS, median (IQR) | 5 (2–5) | 5 (3–5) | 0.513 | 5 (2–5) | 5 (3–5) | 0.615 |
| 8 h VAS, median (IQR) | 3 (0–5) | 3 (0–5) | 0.795 | 3 (0.5–5) | 3 (0–5) | 0.805 |
| 12 h VAS, median (IQR) | 3 (1–5) | 3 (2–5) | 0.852 | 3 (1.25–5) | 3 (2–4.75) | 0.651 |
| 16 h VAS, median (IQR) | 3 (0–4) | 3 (0.75–5) | 0.369 | 3 (0–4) | 3 (0.25–5) | 0.539 |
| 20 h VAS, median (IQR) | 2 (0–3) | 2.5 (0–4) | 0.564 | 2 (0–3) | 2.5 (0–4) | 0.475 |
| 24 h VAS, median (IQR) | 3 (1–4) | 3 (1.5–4) | 0.803 | 3 (1–4) | 3 (2–4) | 0.687 |
| 28 h VAS, median (IQR) | 2 (0–3) | 2 (0–3) | 0.587 | 2 (0–3) | 2 (0–3) | 0.522 |
| 32 h VAS, median (IQR) | 1 (0–2) | 1 (0–3) | 0.935 | 0.5 (0–2.75) | 1 (0–3) | 0.760 |
| 36 h VAS, median (IQR) | 0 (0–3) | 2 (0–3.25) | 0.112 | 0 (0–3) | 2 (0–3.75) | 0.099 |
| 40 h VAS, median (IQR) | 1 (0–3) | 1.5 (0–4) | 0.350 | 0.5 (0–3) | 2 (0–4) | 0.225 |
| 44 h VAS, median (IQR) | 2 (0–3) | 2 (0–3) | 0.954 | 1.5 (0–3) | 2 (0–3) | 0.700 |
| 48 h VAS, median (IQR) | 2 (0–3) | 2 (0–3.25) | 0.524 | 2 (0–2.75) | 2 (0.25–3.75) | 0.228 |
| 52 h VAS, median (IQR) | 1 (0–3) | 2 (0–4) | 0.310 | 1 (0–2) | 2 (0–4) | 0.109 |
| 56 h VAS, median (IQR) | 0 (0–2) | 2 (0–4) | 0.168 | 0 (0–2) | 2 (0–4) | 0.101 |
| 60 h VAS, median (IQR) | 0 (0–2) | 1 (0–3) | 0.608 | 0 (0–2) | 1 (0–3) | 0.449 |
| 64 h VAS, median (IQR) | 1 (0–3) | 0.5 (0–3) | 0.595 | 0.5 (0–3) | 1 (0–3) | 0.986 |
| 68 h VAS, median (IQR) | 1 (0–2) | 1 (0–2.25) | 0.979 | 1 (0–2.75) | 1 (0–2.75) | 0.813 |
| 72 h VAS, median (IQR) | 2 (0–3) | 1 (0–3) | 0.459 | 2 (0–3) | 1 (0–3) | 0.825 |
IQR, interquartile range; VAS, visual analog scale score.